诊断学理论与实践 ›› 2023, Vol. 22 ›› Issue (01): 8-13.doi: 10.16150/j.1671-2870.2023.01.002
陈国群, 蔡姣迪
收稿日期:
2022-12-13
出版日期:
2023-02-25
发布日期:
2023-07-06
基金资助:
CHEN Guoqun, CAI Jiaodi
Received:
2022-12-13
Online:
2023-02-25
Published:
2023-07-06
摘要:
肺癌是全球癌症相关死亡排名第一的癌症,每年约有180万患者死于肺癌,占所有癌症死亡病例的18.0%。非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌的主要类型,在所有肺癌患者中占比超过85%。我国每年的新发肺癌病例超过70万,且每年有超过60万例患者死于肺癌,占所有癌症死亡患者的21.7%。2022年,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)更新了第4版、第5版肺癌临床诊疗指南。相比第3版指南,第4版指南新增了ERBB2(HER2)突变在非小细胞肺癌诊治中的参考意义,更新的内容主要聚焦于HER2突变作为标准生物标志物的检测及HER2突变患者的治疗,推荐对转移性NSCLC患者行HER2突变检测,并推荐将德喜曲妥珠单抗及恩美曲妥珠单抗作为HER2突变阳性患者的二线治疗药物。但这2种药物在我国尚处于临床实验中,对于存在HER2突变的NSCLC患者,其治疗策略还需临床医师结合实际情况综合考量,且需更多的国内实验数据支持。第5版指南则扩大了纳武单抗的使用范围,标志着免疫检查点抑制剂的研究取得了新的进展。
中图分类号:
陈国群, 蔡姣迪. 2022年美国国立综合癌症网络(NCCN)《非小细胞肺癌临床诊疗指南》(第4版及第5版)解读[J]. 诊断学理论与实践, 2023, 22(01): 8-13.
CHEN Guoqun, CAI Jiaodi. Interpretation of the Clinical Practice Guidelines for Non-small Lung Cancer (version 4 and version 5) of 2022 National Comprehensive Cancer Nerwork(NCCN)[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 8-13.
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
doi: 10.3322/caac.v71.3 URL |
[2] |
CHENG M, JOLLY S, QUARSHIE W O, et al. Modern radiation further improves survival in non-small cell lung cancer: an analysis of 288,670 patients[J]. J Cancer, 2019, 10(1):168-177.
doi: 10.7150/jca.26600 pmid: 30662537 |
[3] |
PARASCANDOLA M, XIAO L. Tobacco and the lung cancer epidemic in China[J]. Transl Lung Cancer Res, 2019, 8(Suppl 1):S21-S30.
doi: 10.21037/tlcr URL |
[4] | CAO M, LI H, SUN D, et al. Cancer burden of major cancers in China: A need for sustainable actions[J]. Cancer Commun (Lond), 2020, 40(5):205-210. |
[5] |
CAO M, CHEN W. Epidemiology of lung cancer in China[J]. Thorac Cancer, 2019, 10(1):3-7.
doi: 10.1111/1759-7714.12916 pmid: 30485694 |
[6] |
OFFIN M, FELDMAN D, NI A, et al. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers[J]. Cancer, 2019, 125(24):4380-4387.
doi: 10.1002/cncr.32461 pmid: 31469421 |
[7] |
YANG C Y, YANG J C, YANG P C. Precision management of advanced non-small cell lung cancer[J]. Annu Rev Med, 2020, 71:117-136.
doi: 10.1146/med.2020.71.issue-1 URL |
[8] |
PILLAI R N, BEHERA M, BERRY L D, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium[J]. Cancer, 2017, 123(21):4099-4105.
doi: 10.1002/cncr.30869 pmid: 28743157 |
[9] |
WEI X W, GAO X, ZHANG X C, et al. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer[J]. Thorac Cancer, 2020, 11(6):1512-1521.
doi: 10.1111/tca.v11.6 URL |
[10] |
OU S H, KWAK E L, SIWAK-TAPP C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification[J]. J Thorac Oncol, 2011, 6(5): 942-946.
doi: 10.1097/JTO.0b013e31821528d3 URL |
[11] |
WOLF J, SETO T, HAN JY, et al. Capmatinib in MET exon 14-mutated or met-amplified non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(10):944-957.
doi: 10.1056/NEJMoa2002787 URL |
[12] |
OWADA-OZAKI Y, MUTO S, TAKAGI H, et al. Prognostic impact of tumor mutation burden in patients with completely resected non-small cell lung cancer: brief report[J]. J Thorac Oncol, 2018, 13(8):1217-1221.
doi: 10.1016/j.jtho.2018.04.003 URL |
[13] |
SCHROCK A B, LI S D, FRAMPTON G M, et al. Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic Profi-ling[J]. J Thorac Oncol, 2017, 12(6):932-942.
doi: 10.1016/j.jtho.2017.03.005 URL |
[14] |
MCGRANAHAN N, FURNESS A J, ROSENTHAL R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016, 351(6280):1463-1469.
doi: 10.1126/science.aaf1490 pmid: 26940869 |
[15] |
LI B T, SMIT E F, GOTO Y, et al. Trastuzumab deruxtecan in her2-mutant non-small-cell lung cancer[J]. N Engl J Med, 2022, 386(3):241-251.
doi: 10.1056/NEJMoa2112431 URL |
[16] |
LI B T, SHEN R, BUONOCORE D, et al. Ado-Trastuzumab emtansine for patients with her2-mutant lung cancers: results from a phase Ⅱ basket trial[J]. J Clin Oncol, 2018, 36(24):2532-2537.
doi: 10.1200/JCO.2018.77.9777 URL |
[17] |
ZHOU C, RAMALINGAM S S, KIM T M, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomi-zed clinical trial[J]. JAMA Oncol, 2021, 7(12):e214761.
doi: 10.1001/jamaoncol.2021.4761 URL |
[18] |
RIELY G J, NEAL J W, CAMIDGE D R, et al. Activity and safety of mobocertinib (tak-788) in previously treated non-small cell lung cancer with egfr exon 20 insertion mutations from a phase Ⅰ/Ⅱ trial[J]. Cancer Discov, 2021, 11(7):1688-1699.
doi: 10.1158/2159-8290.CD-20-1598 URL |
[19] |
YUAN B, ZHAO J, ZHOU C, et al. Co-occurring alterations of ERBB2 exon 20 insertion in non-small cell lung cancer (NSCLC) and the potential indicator of response to afatinib[J]. Front Oncol, 2020, 10:729.
doi: 10.3389/fonc.2020.00729 URL |
[20] |
CAPPUZZO F, BEMIS L, VARELLA-GARCIA M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer[J]. N Engl J Med, 2006, 354(24):2619-2621.
doi: 10.1056/NEJMc060020 URL |
[21] |
MAZIÈRES J, PETERS S, LEPAGE B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives[J]. J Clin Oncol, 2013, 31(16):1997-2003.
doi: 10.1200/JCO.2012.45.6095 pmid: 23610105 |
[22] |
MAZIERES J, DRILON A, LUSQUE A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Ann Oncol, 2019, 30(8):1321-1328.
doi: S0923-7534(19)31284-0 pmid: 31125062 |
[23] |
GUISIER F, DUBOS-ARVIS C, VIÑAS F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018[J]. J Thorac Oncol, 2020, 15(4):628-636.
doi: 10.1016/j.jtho.2019.12.129 URL |
[24] |
FAN Y, QIU J, YU R, et al. Clinical and molecular charac-teristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations[J]. Mol Oncol, 2020, 14(8):1731-1739.
doi: 10.1002/mol2.v14.8 URL |
[25] |
FORDE P M, SPICER J, LU S, et al. Neoadjuvant nivo-lumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21):1973-1985.
doi: 10.1056/NEJMoa2202170 URL |
[26] |
HANCOCK J G, ROSEN J E, ANTONICELLI A, et al. Impact of adjuvant treatment for microscopic residual di-sease after non-small cell lung cancer surgery[J]. Ann Thorac Surg, 2015, 99(2):406-413.
doi: 10.1016/j.athoracsur.2014.09.033 URL |
[27] |
WU Y L, TSUBOI M, HE J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18):1711-1723.
doi: 10.1056/NEJMoa2027071 URL |
[28] |
FELIP E, ALTORKI N, ZHOU C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-ⅢA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308):1344-1357.
doi: 10.1016/S0140-6736(21)02098-5 URL |
[1] | 武冬冬, 陈玉辉, 刘芳, 刘银红, 蒋景文. 脑小血管疾病合并中枢神经系统退行性疾病机制的研究进展[J]. 诊断学理论与实践, 2022, 21(05): 644-649. |
[2] | 周思锋, 徐海舒, 范欣生. 基于不同生物样本代谢组学的OSAHS生物标志物研究进展[J]. 诊断学理论与实践, 2022, 21(04): 535-540. |
[3] | 杜海磊, 陈聆, 罗方秀, 李勇, 程齐俭, 朱良纲, 杭钧彪. Beclin-1和Bcl-2表达与非小细胞肺癌患者病理特征及预后间关系的研究[J]. 诊断学理论与实践, 2020, 19(03): 258-263. |
[4] | 陈海燕, 杨小宝, 许大康. 新生物标志物在胃肠道肿瘤中疗效预测和预后价值的研究进展[J]. 诊断学理论与实践, 2019, 18(06): 704-710. |
[5] | 罗清琼, 陈福祥. 肿瘤免疫治疗策略的转变及相关标志物研究现状[J]. 诊断学理论与实践, 2019, 18(04): 387-393. |
[6] | 王晓斐, 高蓓莉. 肺癌免疫治疗标志物研究进展认识[J]. 诊断学理论与实践, 2018, 17(05): 494-498. |
[7] | 张新, 张新宇. 支气管冲洗液基因检测在肺癌诊治中的价值[J]. 诊断学理论与实践, 2018, 17(05): 508-511. |
[8] | 杜坤, 杨喜, 卞炳贤, 任懿倩, 张广慧. 血清presepsin(sCD14-ST)、降钙素原、C反应蛋白和白介细胞素-6诊断血流细菌感染的诊断性能比较[J]. 诊断学理论与实践, 2018, 17(05): 581-585. |
[9] | 顾圣佳, 曹琪琪, 严福华, 杨文洁. 双能CT在非小细胞肺癌非手术治疗疗效评估中的应用价值[J]. 诊断学理论与实践, 2018, 17(05): 526-532. |
[10] | 马韵芳, 潘丽娜, 张培培, 何清, 徐志红, 胡家安. 人类表皮生长因子受体2基因扩增的非小细胞肺癌一例报告[J]. 诊断学理论与实践, 2018, 17(04): 462-465. |
[11] | 崔诗爽, 陈生弟, 王刚. 帕金森病体液生物标志物研究进展[J]. 诊断学理论与实践, 2018, 17(04): 471-476. |
[12] | 牟姗, 陈哲君, 谢园园. 生物标志物在肾脏损伤诊断中的临床应用[J]. 诊断学理论与实践, 2017, 16(04): 358-362. |
[13] | 商慧芳, 陈永平,. 帕金森病生物标志物的研究现状及展望[J]. 诊断学理论与实践, 2016, 15(02): 92-95. |
[14] | 张月琪, 任汝静, 王刚,. 尿液生物标志物对痴呆诊断价值的研究进展[J]. 诊断学理论与实践, 2016, 15(02): 190-194. |
[15] | 杨舟, 王世东, 程磊, 程莉, 陶生策, 宋凯, 张庆华,. 基于凝集素芯片的蛋白质糖基化修饰检测方法[J]. 诊断学理论与实践, 2015, 14(05): 455-460. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||